BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33327228)

  • 1. Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report.
    Misir Krpan A; Rakusic Z; Herceg D
    Medicine (Baltimore); 2020 Dec; 99(50):e22928. PubMed ID: 33327228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab.
    Palacka P; Slopovsky J; Makovnik M; Kajo K; Obertova J; Mego M
    Medicine (Baltimore); 2022 Jan; 101(3):e28613. PubMed ID: 35060532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary pineal melanoma with leptomeningeal spreading: case report and review of the literature.
    Martin-Blondel G; Rousseau A; Boch AL; Cacoub P; Sène D
    Clin Neuropathol; 2009; 28(5):387-94. PubMed ID: 19788056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature.
    Fujimori K; Sakai K; Higashiyama F; Oya F; Maejima T; Miyake T
    Neurosurg Rev; 2018 Jan; 41(1):333-339. PubMed ID: 28986666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
    Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
    Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meningeal melanocytoma with nevus fuscoceruleus ophthalmomaxillaris: report of a case].
    WU C; WANG H; SHI QL; MA HH; LU ZF
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):194-5. PubMed ID: 21575395
    [No Abstract]   [Full Text] [Related]  

  • 7. Spindle cell melanoma coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare collision tumor in multiple sites.
    Dirilenoglu F; Yukselen OO; Mocan G
    J Cutan Pathol; 2020 Dec; 47(12):1215-1219. PubMed ID: 32959377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.
    Viray H; Bradley WR; Schalper KA; Rimm DL; Gould Rothberg BE
    Arch Pathol Lab Med; 2013 Aug; 137(8):1063-73. PubMed ID: 23899062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer.
    Kriegsmann M; Kriegsmann K; Harms A; Longuespée R; Zgorzelski C; Leichsenring J; Muley T; Winter H; Kazdal D; Goeppert B; Warth A
    Diagn Pathol; 2018 Sep; 13(1):68. PubMed ID: 30205833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Atrophy Associated with Primary Diffuse Meningeal Melanomatosis.
    Ma Y; Xing X; Li Y; Ao R; He M; Lan X; Zhao Y; Zhang J; Yu S
    World Neurosurg; 2020 Apr; 136():311-314. PubMed ID: 32004738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of meningeal melanomatosis diagnosed by immunostaining of cerebrospinal fluid].
    Tamura Y; Umeda Y; Umeda M; Oyake M; Usuda H; Fujita N
    Rinsho Shinkeigaku; 2020 Aug; 60(8):565-568. PubMed ID: 32641630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric primary diffuse leptomeningeal melanomatosis: Case report and review of the literature.
    Xu X; Zheng Y; Li J; Wang F; Li F
    Medicine (Baltimore); 2020 Feb; 99(8):e19178. PubMed ID: 32080099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
    J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
    Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
    JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare case of primary clear cell sarcoma of the pubic bone resembling small round cell tumor: an unusual morphological variant.
    Nakayama S; Yokote T; Iwaki K; Akioka T; Miyoshi T; Hirata Y; Takayama A; Nishiwaki U; Masuda Y; Tsuji M; Hanafusa T
    BMC Cancer; 2012 Nov; 12():538. PubMed ID: 23170958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
    Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
    Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?
    Gaspard M; Lamant L; Tournier E; Valentin T; Rochaix P; Terrier P; Ranchere-Vince D; Coindre JM; Filleron T; Le Guellec S
    Histopathology; 2018 Dec; 73(6):969-982. PubMed ID: 30137667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.